Novartis AG
NYSE:NVS

Watchlist Manager
Novartis AG Logo
Novartis AG
NYSE:NVS
Watchlist
Price: 147.13 USD 1.47% Market Closed
Market Cap: $297.9B

Relative Value

The Relative Value of one NVS stock under the Base Case scenario is hidden USD. Compared to the current market price of 147.13 USD, Novartis AG is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NVS Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

NVS Competitors Multiples
Novartis AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
Novartis AG
NYSE:NVS
221.9B USD 5 19.5 15.7 20.2
US
Eli Lilly and Co
NYSE:LLY
1T USD 17 54.8 36.8 39.4
UK
Dechra Pharmaceuticals PLC
F:1PK
5.1B EUR 6.8 -184.5 42.7 196.5
US
Johnson & Johnson
NYSE:JNJ
528.7B USD 5.6 19.7 13.8 16.9
CH
Roche Holding AG
SIX:ROG
275.3B CHF 4.5 29.2 12.4 14.5
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP 4.9 30.2 19.7 28.8
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 5.6 17.2 11.9 13.9
US
Merck & Co Inc
NYSE:MRK
267.9B USD 4.2 14.1 10 11.8
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
145.6B USD 2.3 14.8 7.5 10.3
FR
Sanofi SA
PAR:SAN
96.5B EUR 1.4 7 6.4 6.4
P/E Multiple
Earnings Growth PEG
CH
Novartis AG
NYSE:NVS
Average P/E: 23
19.5
17%
1.1
US
Eli Lilly and Co
NYSE:LLY
54.8
54%
1
UK
D
Dechra Pharmaceuticals PLC
F:1PK
Negative Multiple: -184.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.7
6%
3.3
CH
Roche Holding AG
SIX:ROG
29.2
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.2
38%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
17.2
2%
8.6
US
Merck & Co Inc
NYSE:MRK
14.1
14%
1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
27%
0.5
FR
Sanofi SA
PAR:SAN
7
25%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CH
Novartis AG
NYSE:NVS
Average EV/EBITDA: 47.4
15.7
6%
2.6
US
Eli Lilly and Co
NYSE:LLY
36.8
34%
1.1
UK
D
Dechra Pharmaceuticals PLC
F:1PK
42.7
36%
1.2
US
Johnson & Johnson
NYSE:JNJ
13.8
2%
6.9
CH
Roche Holding AG
SIX:ROG
12.4
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
19.7
10%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.9
1%
11.9
US
Merck & Co Inc
NYSE:MRK
10
6%
1.7
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
FR
Sanofi SA
PAR:SAN
6.4
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CH
Novartis AG
NYSE:NVS
Average EV/EBIT: 111.2
20.2
12%
1.7
US
Eli Lilly and Co
NYSE:LLY
39.4
37%
1.1
UK
D
Dechra Pharmaceuticals PLC
F:1PK
196.5
98%
2
US
Johnson & Johnson
NYSE:JNJ
16.9
6%
2.8
CH
Roche Holding AG
SIX:ROG
14.5
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
28.8
23%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.9
0%
N/A
US
Merck & Co Inc
NYSE:MRK
11.8
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5
FR
Sanofi SA
PAR:SAN
6.4
15%
0.4